| Title : The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study - Mohler_2008_J.Am.Coll.Cardiol_51_1632 |
| Author(s) : Mohler ER, 3rd , Ballantyne CM , Davidson MH , Hanefeld M , Ruilope LM , Johnson JL , Zalewski A |
| Ref : J Am Coll Cardiol , 51 :1632 , 2008 |
| Abstract : Mohler_2008_J.Am.Coll.Cardiol_51_1632 |
| ESTHER : Mohler_2008_J.Am.Coll.Cardiol_51_1632 |
| PubMedSearch : Mohler_2008_J.Am.Coll.Cardiol_51_1632 |
| PubMedID: 18436114 |
Mohler ER, 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A (2008)
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study
J Am Coll Cardiol
51 :1632
Mohler ER, 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A (2008)
J Am Coll Cardiol
51 :1632